Four-site, Randomized, Parallel Design, Double-blind, Placebo-controlled, 10-week Trial of Donepezil 10 mg Daily for Verbal Memory Problems Among Adults With TBI in the Subacute or Chronic Recovery Period
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs Donepezil (Primary)
- Indications Memory disorders
- Focus Therapeutic Use
- Acronyms MEMRI-TBI-D
- 26 Dec 2018 Planned End Date changed from 1 Sep 2018 to 30 Sep 2019.
- 26 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2014 New trial record